Demis Hassabis
British AI researcher; DeepMind co-founder and 2024 Nobel laureate in Chemistry
Profile
- Nationality
- British (born in London in 1976)
- Field
- Artificial intelligence, cognitive neuroscience, game development
- Career
- Coded the game Theme Park (aged 17); founded Elixir Studios; co-founder and CEO, DeepMind (2010); CEO, Google DeepMind (April 2023–August 2026); founder and CEO, Isomorphic Labs (2021)
- Now (Oct 2026)
- Chair of Google DeepMind and Chief Scientist of Alphabet (since August 2026); CEO of Isomorphic Labs
- Major awards
- Nobel Prize in Chemistry (2024); knighthood (2024); CBE (2018); Fellow of the Royal Society
Demis Hassabis is an artificial intelligence researcher born in London, England, in 1976. He was a chess prodigy as a child, and at 17 he coded Theme Park, a computer game that sold millions of copies. After graduating from the University of Cambridge with a Double First (top honours) in computer science, he founded the games company Elixir Studios. He later returned to university and in 2009 earned a PhD in cognitive neuroscience (the study of how the brain remembers and thinks) from University College London (UCL). During his PhD he studied how the brain recalls past experiences and imagines the future.
In 2010 he co-founded the AI company DeepMind in London with Shane Legg and Mustafa Suleyman, and Google bought the company in 2014. DeepMind's Go-playing AI, AlphaGo, beat Lee Sedol 4–1 in Seoul in March 2016. In 2020 he and John Jumper presented AlphaFold2, an AI that predicts the three-dimensional structure of proteins. Proteins are the substances that drive the chemical reactions at the basis of life, and AlphaFold2 is widely used in areas such as research into new medicines. For this work the two shared the 2024 Nobel Prize in Chemistry with David Baker. In April 2023 he became CEO of Google DeepMind, formed by combining DeepMind with Google's Brain team.
In 2021 he founded Isomorphic Labs, a company that uses AI to design medicines, and became its CEO. The company announced in May 2026 that it had raised $2.1 billion in investment (company-reported). On 5 August 2026 he handed day-to-day running of Google DeepMind to Koray Kavukcuoglu and became Chair of Google DeepMind and Chief Scientist of Alphabet, Google's parent company. The aim was to focus more on the big picture of artificial general intelligence (AGI: AI that can do a wide range of tasks as well as people), on science and on his work at Isomorphic Labs. Google CEO Sundar Pichai noted that Hassabis has described the present as 'the foothills of the singularity' (a turning point at which technology starts advancing explosively). He was also knighted in 2024 for services to AI. As of October 2026 he is Chair of Google DeepMind, Chief Scientist of Alphabet and CEO of Isomorphic Labs.
Sources for this profile (10) · as of Oct 31, 2026
- Demis Hassabis – Facts – 2024 · NobelPrize.org
- Press release: The Nobel Prize in Chemistry 2024 · NobelPrize.org (Royal Swedish Academy of Sciences)
- Neuroscience, intuition and superhumans – how DeepMind co-founder and UCL alumnus Demis Hassabis is leading the AI revolution · University College London
- Smart tech, smarter minds: Demis Hassabis, AI and neuroscience trailblazer · University College London
- UCL alumni knighted as leaders in film and AI · University College London
- Sir Demis Hassabis, PhD – Founder and CEO · Isomorphic Labs
- Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine · Isomorphic Labs
- AlphaGo · Google DeepMind
- Google DeepMind: Bringing together two world-class AI teams · Google (The Keyword)
- The next chapter of our AI momentum · Google (The Keyword)
AIMade by AIThis profile was written by AI (Claude) from the 10 sources above (official pages, filings, news reports).How it's made
Records 3
Newest first. Open one to see it with its source.
A defining 2026 remark showing a shift from the earlier, cautious way of talking about AGI timelines to a more assertive framing
His relatively conservative 5–10-year estimate contrasted with the near-term predictions of Altman and Aschenbrenner, highlighting the spread among lab CEOs
The reference point for the cautiously optimistic camp